TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03213002: Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

Sponsor: Northwell Health · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 67 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT03213002 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03213002 Rescue Dossier →